MRSN logo

MRSN
Mersana Therapeutics Inc

2,898
Mkt Cap
$137.57M
Volume
30,741.00
52W High
$70.73
52W Low
$5.21
PE Ratio
-1.98
MRSN Fundamentals
Price
$27.85
Prev Close
$27.52
Open
$27.57
50D MA
$14.20
Beta
1.90
Avg. Volume
245,811.47
EPS (Annual)
-$14.12
P/B
-2.34
Rev/Employee
$397,029.41
Loading...
Loading...
News
all
press releases
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages
Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has earned a consensus recommendation of "Reduce" from the eight brokerages that are presently covering the company, Marketbeat Ratings...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their...
PR Newswire·6d ago
News Placeholder
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm...
PR Newswire·6d ago
News Placeholder
Wedbush Lowers Earnings Estimates for Mersana Therapeutics
Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Research analysts at Wedbush dropped their FY2028 earnings estimates for shares of Mersana Therapeutics in a report issued on Thursday...
MarketBeat·16d ago
News Placeholder
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to...
PR Newswire·17d ago
News Placeholder
Mersana Therapeutics (NASDAQ:MRSN) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS
Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) released its earnings results on Friday. The company reported ($1.51) earnings per share for the quarter, missing analysts' consensus estimates of...
MarketBeat·17d ago
News Placeholder
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Mersana Therapeutics, Inc. (NasdaqGS: MRSN) to...
Business Wire·17d ago
News Placeholder
Mersana Therapeutics (NASDAQ:MRSN) Rating Lowered to "Hold" at Leerink Partnrs
Leerink Partnrs cut shares of Mersana Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday...
MarketBeat·18d ago
News Placeholder
Lifesci Capital Downgrades Mersana Therapeutics (NASDAQ:MRSN) to Hold
Lifesci Capital lowered shares of Mersana Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday...
MarketBeat·18d ago
News Placeholder
Guggenheim Reiterates Neutral Rating for Mersana Therapeutics (NASDAQ:MRSN)
Guggenheim restated a "neutral" rating on shares of Mersana Therapeutics in a report on Friday...
MarketBeat·19d ago

Latest MRSN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.